Neurotrophic Keratitis Clinical Trial
Official title:
A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO Study
The primary objectives are to evaluate the long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 Neurotrophic Keratitis (NK) patients who enrolled in the DEFENDO Study.
This clinical study will be a multi-center, open label, long term follow-up study of the patients who were enrolled in the DEFENDO Study who had Stage 1 Neurotrophic Keratitis (NK) who were treated with OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution. The DEFENDO Long-Term Follow-up Study will have follow-up with the patients at month 24-30 post-treatment in the DEFENDO Study: All patients will be evaluated in a real-world setting post the enrollment in the DEFENDO Study through 30 months. Patients will be treated per standard of care as determined by the Investigator and will document topical ophthalmic medications. The original DEFENDO Study duration was for a total of 34 weeks: a screening period of 2 weeks, followed by enrollment in 8 weeks of OXERVATE™ treatment and an Off- Treatment Follow-Up of 6 months. After completing enrollment in the original DEFENDO Study, patients will be invited to enter the DEFENDO Long- Term Follow-up Study (all standard of care is permitted). Two additional long-term follow-up visits will occur at 24- and 30-months to evaluate long-term clinical outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04485546 -
Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
|
Phase 4 | |
| Not yet recruiting |
NCT05927428 -
Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
|
Phase 2 | |
| Completed |
NCT04552730 -
Nerve Growth Factor for the Treatment of Cornea Disease
|
||
| Recruiting |
NCT04276558 -
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
|
Phase 2 | |
| Recruiting |
NCT04573647 -
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
|
||
| Completed |
NCT04820010 -
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
|
||
| Recruiting |
NCT04627571 -
Corneal Nerves After Treatment With Cenegermin
|
||
| Enrolling by invitation |
NCT05758753 -
QST for Corneal Nerve Function
|
N/A | |
| Terminated |
NCT05809245 -
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
|
N/A | |
| Withdrawn |
NCT05321251 -
Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
|
Phase 2/Phase 3 | |
| Terminated |
NCT03037450 -
Miniinvasive Corneal Neurotization. A Pilot Study.
|
N/A | |
| Not yet recruiting |
NCT06364657 -
Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
|
||
| Recruiting |
NCT05566717 -
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
|
||
| Not yet recruiting |
NCT02707120 -
Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis
|
Phase 4 | |
| Completed |
NCT01756456 -
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
|
Phase 1/Phase 2 | |
| Completed |
NCT02227147 -
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
|
Phase 2 | |
| Recruiting |
NCT04909450 -
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
|
Phase 1/Phase 2 |